Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

<jats:title>Summary</jats:title><jats:p>Pituitary carcinomas are rare, accounting for about 0·2% of all pituitary tumours. They represent a challenge to clinical practice in both diagnosis and treatment. They may present initially as typical pituitary adenomas, with a delayed appearance of aggressive signs, or as aggressive tumours from the outset. Predicting the pituitary tumour behaviour remains difficult: increased mitotic, <jats:styled-content style="fixed-case">K</jats:styled-content>i‐67 and <jats:styled-content style="fixed-case">P</jats:styled-content>53 indices might be associated with tumour aggression. The treatment of pituitary carcinomas and aggressive pituitary tumours includes surgery, adjuvant medical treatment, external beam radiotherapy and chemotherapy. Until recently, the treatment of pituitary carcinomas was mainly palliative and did not seem to increase overall survival. Recent case reports have detailed the successful use of temozolomide, an orally administered alkylating agent used to treat malignant gliomas, in the management of pituitary carcinomas and aggressive pituitary tumours. The outcome of treatment might depend on the expression of <jats:styled-content style="fixed-case"> <jats:roman>O</jats:roman> <jats:sup>6</jats:sup> </jats:styled-content>‐methylguanine‐<jats:styled-content style="fixed-case">DNA</jats:styled-content> methyltransferase (<jats:styled-content style="fixed-case">MGMT</jats:styled-content>), a <jats:styled-content style="fixed-case">DNA</jats:styled-content> repair enzyme that potentially interferes with drug efficacy. This review describes the clinical presentation and response to temozolomide in 44 patients with pituitary carcinomas or aggressive pituitary tumours reported in the literature. The results suggest that temozolomide should be considered a drug of major importance in the therapeutic algorithm of aggressive pituitary tumours and pituitary carcinomas. Because of the inconsistency of published data, <jats:styled-content style="fixed-case">MGMT</jats:styled-content> expression should probably not be taken as a reason to deny these patients the potential benefit of temozolomide treatment, taking into account the paucity of other available treatments.</jats:p>